Evidence map›Paper›PMID 37209290›Full record

ArticleJournal of neuro-oncology2023

Palliative care referral across the disease trajectory in high-grade glioma.

Rita C Crooms, Jennie W Taylor, Nathalie Jette, Rachelle Morgenstern, Parul Agarwal, Nathan E Goldstein, Barbara G Vickrey

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. From diagnosis to daily realities: longitudinal phenomenological exploration of symptom trajectories in glioma survivorship.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Rita C CroomsDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. caroline.crooms@mssm.edu.
Jennie W TaylorDepartments of Neurology and Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Nathalie JetteDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Rachelle MorgensternDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Parul AgarwalDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nathan E GoldsteinBrookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Barbara G VickreyDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Icahn School of Medicine at Mount Sinai · USUniversity of California, San Francisco · US

Funding

Residing in the Community with Dementia at the End of Life: Understanding Hospice Use and Residential SettingP30AG028741 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ALBERT L SIU · 2010 to 2026
$21.9M
Palliative Care for High-Grade GliomaR03AG074064 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CROOMS, RITA CAROLINE · 2021 to 2022
$338k
NIA NIH HHS AG074064-01NIA NIH HHS L30 AG079438NIA NIH HHS P30 AG028741NIA NIH HHS R03 AG074064
6 · The paper itself

Abstract

purposeAdults with high-grade glioma (HGG), WHO grade III or IV, have substantial palliative care needs. Our aim was to determine occurrence, timing, and factors associated with palliative care consultation (PCC) in HGG at one large academic institution.

methodsHGG patients receiving care between 08/1/2011 and 01/23/2020 were identified retrospectively from a multi-center healthcare system cancer registry. Patients were stratified by any PCC (yes/no), and timing of initial PCC by disease phase: diagnosis (before radiation), during initial treatment (first-line chemotherapy/radiation), second-line treatment(s), or end-of-life (after last chemotherapy).

resultsOf 621 HGG patients, 134 (21.58%) received PCC with the vast majority occurring during hospital admission [111 (82.84%)]. Of the 134, 14 (10.45%) were referred during the diagnostic phase; 35 (26.12%) during initial treatment; 20 (14.93%) during second-line treatment; and 65 (48.51%) during end of life. In multivariable logistic regression, only higher Charlson Comorbidity Index was associated with greater odds of PCC [OR 1.3 (95% CI 1.2-1.4), p < 0.01]; but not age or histopathology. Patients who received PCC prior to end of life had longer survival from diagnosis than those referred during end of life [16.5 (8, 24) months vs. 11 (4, 17); p < 0.01].

conclusionA minority of HGG patients ever received PCC, which primarily occurred in the inpatient setting, and nearly half during the end-of-life phase. Thus, only about one in ten patients in the entire cohort potentially received the benefits of earlier PCC despite earlier referral having an association with longer survival. Further studies should elucidate barriers and facilitators to early PCC in HGG.

Indexed as

GliomaPalliative CareAdultDeathHumansReferral and ConsultationRetrospective StudiesCare trajectoriesGliomaPalliative careQuality of life

Identifiers

PMID37209290
PMCPMC10546385
OpenAlexW4377140087

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.